Investing.com – India equities were higher at the close on Thursday, as gains in the Consumer Durables, Capital Goods and Real Estate sectors propelled shares higher. At the close...
The BSE SENSEX closed at 35,929.64, up by 150.57 points, or by 0.42 per cent, and the NSE Nifty ended at 10,791.55, up by 53.95 points, or by 0.50 per cent.
* NSE, BSE indexes up 0.7 pct each * Easing inflation increases chances of interest rate hold * Banks rally on new RBI chief By Chris Thomas Dec 13 (Reuters) - Indian shares...
(1) Sun Pharma (NS:SUN): We have been maintaining a 'Bearish' view on this stock since it formed a Head and Shoulders Pattern in Oct-Nov series. Although the stock has fallen a...
(1) Infosys (NS:INFY): The stock was in a retracement phase since October and has recently started to form a base which indicates at an ongoing surging demand in the counter. A...
|Type||5 mins||15 mins||Hourly||Daily||Monthly|
|Moving Averages||Sell||Strong Sell||Strong Sell||Sell||Strong Sell|
|Technical Indicators||Sell||Strong Sell||Strong Sell||Strong Sell||Strong Sell|
|Summary||Sell||Strong Sell||Strong Sell||Strong Sell||Strong Sell|
Filter Table By:
|Pattern||Timeframe||Reliability||Candles Ago||Candle Time|
|Three Black Crows||1M||1||Nov 18|
|Three Outside Up||1D||1||Dec 12, 2018|
|Bullish Engulfing||1D||2||Dec 11, 2018|
|Advance Block Bearish||5H||3||Dec 12, 2018 07:30|
|Deliberation Bearish||5H||3||Dec 12, 2018 07:30|
Sun Pharmaceutical Industries Limited is a pharmaceuticals company. The Company's business segments include US Business, Indian Branded Generics Business, Emerging Markets, Global Consumer Healthcare Business and Active Pharmaceutical Ingredients (API). Its Rest of World segment includes Western Europe, Canada, Australia, New Zealand and other markets. The Company offers its products to therapy areas, such as cardiology, neuro-psychiatry, gastroenterology, anti-infective, diabetology and dermatology. The Company's products include AB PHYLLINE, ABZORB DUSTING POWDER, ACAMPROL, ACOSTIN 3 MIU, ACOSTIN FORTE and AB PHYLLINE SR 200. Its manufacturing units are situated in India, the United States and Brazil, among others. Its units produce generics, branded generics, specialty products, over-the-counter (OTC) products, anti-retroviral (ARVs) and APIs. They also produce intermediates in a range of dosage forms, including tablets, capsules, injectables, ointments, creams and liquids.Read More
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.